Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
It is currently the only vaccine authorized by the Drug Controller General of India (DCGI) for active immunization against HEV in adults aged 18 to 65
China has the highest number of clinical trials that were initiated in NAFLD in the APAC region over the past decade.
The objective of this study is to evaluate the efficacy of ASC22 (Envafolimab) combined with Chidamide on the viral reservoirs of latently infected cells in HIV patients.
This is the company’s first partnership arrangement in China
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
Subscribe To Our Newsletter & Stay Updated
